Heart Failure

Heart failure occurs when the heart cannot pump as much blood as the body requires. This ineffective pumping can lead to enlargement of the heart as the myocardium works harder pump the same amount of blood. Heart failure may be caused by defects in the myocardium, such as an a heart attack infarct, or due to structural issues such as severe heart valve regurgitation. Heart failure can be divided into HF with preserved ejection fraction (HFpEF), and HF with reduced ejection fraction (HFrEF). The disease is further divided into four New York Heart Association (NYHA) classes. Stage IV heart failure is when the heart is completely failing and requires a heart transplant or hemodynamic support from a left ventricular assist device (LVAD).

Transcatheter heart failure implant from Ancora Heart linked to positive 2-year data
The flexible device is attached to the inner wall of the left ventricle during a minimally invasive procedure. It was designed to reduce the size of the left ventricle over time.
Hospital in Mexico earns first heart failure certification of its kind
A facility outside the United States has received the American Heart Association's Comprehensive Heart Failure Center Certification for the first time.
FDA announces recall for Johnson & Johnson devices due to cybersecurity risk—customers urged to act
The FDA and Johnson & Johnson MedTech are telling customers to keep the devices in a secure environment until they can be disabled from all networks.
New expert guidelines examine the use of temporary MCS during heart surgery
Three leading medical societies collaborated on the new document, providing detailed recommendations that cover a wide variety of technologies and clinical scenarios.
FDA approves subcutaneous diuretic treatment for heart failure-related edema
The newly approved drug-device combination helps patients manage their own treatment from the comfort of home.

Vulnerable, but treatable: Semaglutide reduces symptoms in high-risk heart failure patients

Yes, even frail HFpEF patients see significant benefits when treated with semaglutide. Researchers believe these new data may help ease the minds of cardiologists everywhere.

heart data research doctor cardiologist AI

America’s heart failure epidemic is getting worse

Approximately one in four Americans will develop heart failure in their lifetime, according to a new report from the Heart Failure Society of America. What can be done to combat this worrisome trend?

Corstasis Therapeutics bumetanide nasal spray Enbumyst

FDA approves nasal spray for edema associated with congestive heart failure

The newly approved intranasal loop diuretic can also be used to treat edema in patients with liver and kidney disease.

Real-world data link semaglutide, tirzepatide to improved heart failure outcomes

GLP-1 drugs have been taking the United States by storm in recent years. According to a new study of more than 90,000 patients, some of these medications can also make a big impact on reducing adverse heart failure outcomes.

Johnson & Johnson MedTech Automated Impella Controller

FDA details new risk with Johnson & Johnson heart pump controllers after patient’s death

This latest alert was put in place after Johnson & Johnson MedTech learned that some of its Automated Impella Controllers were built to the wrong specifications, impacting their ability to function. Affected devices should not be used going forward.

The U.S. Food and Drug Administration (FDA) updated the Breakthrough Device Program designations data this week, which now includes 1,176 Breakthrough Device designations, of which 160 have gained market clearance. Cardiovascular devices lead these with 243 devices, the highest number out of all other clinical categories. This includes 16 new cardiovascular devices cleared in the past year.

Cardiovascular device approvals continue to lead the FDA's Breakthrough Device Program

Cardiology is number one in FDA Breakthrough Device designations at 218, the highest number out of all other clinical categories. This includes 16 new devices cleared in the past year.

FDA announces Class I recalls for heart pump accessories due to safety risk

Abbott has warned healthcare providers about a new issue with the mobile power units of certain HeartMate 3 LVADs.

Palliative care plays an essential role in heart failure care

New HFSA recommendations highlight the importance of integrating palliative care into the day-to-day care of heart failure patients.

Heart Failure

Transcatheter heart failure implant from Ancora Heart linked to positive 2-year data

Hospital in Mexico earns first heart failure certification of its kind

FDA announces recall for Johnson & Johnson devices due to cybersecurity risk—customers urged to act

New expert guidelines examine the use of temporary MCS during heart surgery

FDA approves subcutaneous diuretic treatment for heart failure-related edema